Advice

in the absence of a submission from the holder of the marketing authorisation:

sirolimus (Rapamune®) is not recommended for use within NHSScotland.

Indication under review: treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
sirolimus (Rapamune)
SMC ID:
SMC2126
Indication:
Treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.
Pharmaceutical company
Pfizer Ltd
BNF chapter
Respiratory system
Submission type
Non submission
Status
Not recommended
Date advice published:
08 October 2018